News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ocular Therapeutix, Inc. (OCUL) Announces Closing Of Initial Public Offering



7/31/2014 10:54:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today the closing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $13.00 per share, resulting in net proceeds of approximately $60.5 million after deducting underwriting discounts and commissions, and estimated offering expenses. All of the shares of common stock in the offering were sold by Ocular Therapeutix.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES